Table 3.
Complications and clinical outcomes
| Overall (n = 132) | Angiotensin II (n = 65) | Control (n = 67) | Effect estimatea (95% CI) | p * | |
|---|---|---|---|---|---|
| Days of use of angiotensin II | 5 (3–6) | 5 (3–6) | – | – | – |
| Organ support during a hospital stay— no. (%) | |||||
| Renal replacement therapy | 32/122 (26.2) | 16/62 (25.8) | 16/60 (26.7) | RD, −4.13 (−19.03 to 10.77) | 0.588 |
| ECMO | 12/124 (9.7) | 5/64 (7.8) | 7/60 (11.7) | RD, −4.15 (−14.84 to 6.55) | 0.449 |
| Prone positioning | 98/124 (79.0) | 54/63 (85.7) | 44/61 (72.1) | RD, 15.40 (0.88–29.92) | 0.040 |
| Complications—no. (%) | |||||
| Stroke | 2/126 (1.6) | 1/65 (1.5) | 1/61 (1.6) | RD, −0.27 (−4.88 to 4.34) | 0.909 |
| Acute myocardial infarction | 1/124 (0.8) | 0/64 (0.0) | 1/60 (1.7) | RD, −1.78 (−5.07 to 1.51) | 0.291 |
| Unexpected cardiac arrest | 14/125 (11.2) | 7/65 (10.8) | 7/60 (11.7) | RD, −4.92 (−15.92 to 6.07) | 0.382 |
| Acute kidney injury | 94/129 (72.9) | 50/65 (76.9) | 44/64 (68.8) | RD, 5.47 (−9.80 to 20.74) | 0.484 |
| Cardiac arrhythmia | 10/127 (7.9) | 5/65 (7.7) | 5/62 (8.1) | RD, −2.10 (−10.15 to 5.94) | 0.609 |
| Clinical outcomes | |||||
| Ventilator‐free days at Day 28 | 0 (0–15) | 0 (0–15) | 1 (0–15) | MD, −0.96 (−4.46 to 2.54) | 0.592 |
| ICU‐free days at Day 28 | 0 (0–12) | 0 (0–10) | 0 (0–13) | MD, 0.00 (−2.33 to 2.34) | 0.999 |
| Hospital‐free days at Day 28 | 0 (0–0) | 0 (0–0) | 0 (0–0) | MD, −0.00 (−3.15 to 3.15) | 0.999 |
| ICU mortality—no. (%) | 57 (43.2) | 33 (50.8) | 24 (35.8) | RD, 10.70 (−6.02 to 27.42) | 0.212 |
| Hospital mortality—no. (%) | 62 (47.0) | 35 (53.8) | 27 (40.3) | RD, 10.65 (−6.49 to 27.80) | 0.226 |
| 60‐Day hospital mortality—no. (%) | 58 (43.9) | 32 (49.2) | 26 (38.8) | HR, 1.18 (0.68–2.03) | 0.560 |
Note: Data are median (Quartile 25th–75th) and N/Total (%).
Abbreviations: CI, confidence interval; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; ICU, intensive care unit; MD, median difference; RD, risk difference.
a
All models adjusted for diabetes, ventilatory support, SpO2, and noradrenaline dose at ICU admission, and considering the hospital of admission as a random effect.
*
p = 0.950 for Schoenfeld residuals.